Impact of Antiretroviral Therapy on Kidney Disease in HIV Infected Individuals – A Qualitative Systematic Review

IF 2.2 Q3 INFECTIOUS DISEASES

Journal of the International Association of Providers of AIDS Care Pub Date : 2022-01-01 DOI:10.1177/23259582221089194

Harsha Adnani, Nirav Agrawal, A. Khatri, Jaclyn Vialet, Meng Zhang, J. Cervia

{"title":"Impact of Antiretroviral Therapy on Kidney Disease in HIV Infected Individuals – A Qualitative Systematic Review","authors":"Harsha Adnani, Nirav Agrawal, A. Khatri, Jaclyn Vialet, Meng Zhang, J. Cervia","doi":"10.1177/23259582221089194","DOIUrl":null,"url":null,"abstract":"Kidney disease is the fourth most common cause of non-AIDS-related mortality in people living with HIV. Combination antiretroviral therapy (cART) remains the cornerstone of treatment. However, little is known about the impact of cART on disease outcomes in patients with HIV-associated nephropathy (HIVAN) and HIV-immune complex kidney disease (HIVICK). This systematic review evaluates the impact of cART on progression to end-stage kidney disease (ESKD) and other outcomes in HIV-infected individuals. We conducted a literature search utilizing PubMed, and Cochrane database and 11 articles met inclusion criteria for analysis of which nine HIVAN studies showed decreased progression to ESKD or death for subjects when treated with cART versus those untreated. However, two studies showed no survival advantage with cART. Three HIVICK studies showed improvement in delaying ESKD in subjects on cART compared to untreated subjects. cART appeared to reduce the risk to ESKD or death in patients with both HIVAN and HIVICK.","PeriodicalId":17328,"journal":{"name":"Journal of the International Association of Providers of AIDS Care","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International Association of Providers of AIDS Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23259582221089194","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 2

Abstract

Kidney disease is the fourth most common cause of non-AIDS-related mortality in people living with HIV. Combination antiretroviral therapy (cART) remains the cornerstone of treatment. However, little is known about the impact of cART on disease outcomes in patients with HIV-associated nephropathy (HIVAN) and HIV-immune complex kidney disease (HIVICK). This systematic review evaluates the impact of cART on progression to end-stage kidney disease (ESKD) and other outcomes in HIV-infected individuals. We conducted a literature search utilizing PubMed, and Cochrane database and 11 articles met inclusion criteria for analysis of which nine HIVAN studies showed decreased progression to ESKD or death for subjects when treated with cART versus those untreated. However, two studies showed no survival advantage with cART. Three HIVICK studies showed improvement in delaying ESKD in subjects on cART compared to untreated subjects. cART appeared to reduce the risk to ESKD or death in patients with both HIVAN and HIVICK.

查看原文本刊更多论文

抗逆转录病毒治疗对HIV感染者肾脏疾病的影响——一项定性系统评价

肾脏疾病是艾滋病毒感染者非艾滋病相关死亡的第四大常见原因。联合抗逆转录病毒疗法(cART)仍然是治疗的基石。然而，cART对hiv相关肾病(HIVAN)和hiv免疫复杂肾病(HIVICK)患者疾病结局的影响知之甚少。本系统综述评估了cART对hiv感染者进展为终末期肾病(ESKD)和其他结局的影响。我们利用PubMed和Cochrane数据库进行了文献检索，11篇文章符合纳入标准，其中9篇HIVAN研究显示，与未治疗的受试者相比，接受cART治疗的受试者进展为ESKD或死亡减少。然而，两项研究显示cART没有生存优势。三项HIVICK研究显示，与未治疗的受试者相比，cART患者延迟ESKD有所改善。cART似乎可以降低HIVAN和HIVICK患者发生ESKD或死亡的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the International Association of Providers of AIDS Care Medicine-Dermatology

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

13 weeks